Has Geoffrey Tyson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $17,171 in general payments to Geoffrey Tyson, MD across 293 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Geoffrey Tyson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Geoffrey Tyson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Geoffrey Tyson, MD

Pain Medicine · Mountlake Terrace, WANPI 1679610778

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (51.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Boston Scientific at 27.6% of the total.

$17,171in general payments, 2019–2025

Across 293 payments — averaging $58.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$5K
Abbott$2K
Medtronic$2K
Vertiflex, Inc.$2K
Nalu Medical, Inc.$1K
Si-bone, Inc.$1K
plus $4K from 23 others

What the payments were for

Travel & lodging$8,22548%
Food & beverage$8,83751%
Education$1091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	104	$4,746
Abbott	24	$2,166
Medtronic	25	$2,071
Vertiflex, Inc.	10	$2,052
Nalu Medical, Inc.	16	$1,246
Si-bone, Inc.	9	$1,182
MML US, Inc.	5	$640
Pfizer	27	$554
Painteq LLC	7	$407
Nevro Corp.	8	$392
Curonix LLC	3	$331
Assertio Therapeutics, Inc.	15	$257
Vertos Medical, Inc.	5	$222
SPR Therapeutics, Inc	3	$216
Biotronik NRO, Inc.	5	$157
Amgen	5	$94
Saluda Medical Americas, Inc.	4	$88
Stimwave Technologies Incorporated	3	$84
Relievant Medsystems, Inc.	2	$39
Collegium Pharmaceutical, Inc.	2	$35
Supernus Pharmaceuticals, Inc.	2	$31
MDD US Operations, LLC	2	$31
Vertex	1	$31
Lundbeck LLC	1	$22
Pernix Therapeutics Holdings, Inc.	1	$18
Sentynl Therapeutics, Inc.	1	$17
Kaleo, Inc.	1	$17
Scilex Pharmaceuticals Inc.	1	$12
Almatica Pharma LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Superion ISS$1,866
PROCLAIM$1,663
KYPHON EXPRESS II KYPHOPAK TRAY$1,450
IFUSE IMPLANT SYSTEM$1,025
Nalu Neurostimulation System$835
ReActiv8$591
SPECTRA WAVEWRITER$343
PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$266
GENERAL PAIN MANAGEMENT$139
mild Device Kit$134
SPRINT PNS System$134
Infinion 16$116
Senza$113
Intracept$105

How this compares

$17,171 in reported general payments places this provider in the 85th percentile of 124 pain medicine providers in Washington.

See all pain medicine providers in Washington →

Medicare billing

Part B allowed, 2024

$140,250

Medicare patients

129

Services billed

2,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Buprenorphine	74	$19,428
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	88	$2,909
Buprenorphine Hcl	59	$2,580
Oxycodone Hcl	130	$2,289
Fentanyl	13	$2,282
Morphine Sulfate ErMorphine Sulfate	23	$1,178
Gabapentin	27	$961
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	26	$783
Pregabalin	34	$609
Hydromorphone Hcl	29	$586
Baclofen	20	$444
Tramadol Hcl	15	$419
Cephalexin	15	$243
Amitriptyline Hcl	12	$114
Celecoxib	12	$80

Paid to pharmacies, not to this prescriber.

Other pain medicine in Mountlake Terrace

Jennifer LeeKirkland$318K
Steven StanosSeattle$206K
Corrie AndersonSeattle$102K
Gregory TermanSeattle$95K
Caroline HarstroemEverett$74K
Sloane YuVancouver$42K
Praveen MambalamEdmonds$32K
Miroslav BackonjaSeattle$22K
Ross VogelgesangOlympia$21K
Jon HillyerSilverdale$20K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →